The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of the Use of Traditional Korean Medicine to Treat a Patient with Chronic Hepatitis B Whose HBV-DNA Level Failed to Drop Below Undetectable Levels Following Long-term Treatment with Entecavir

Entecavir와 한의약 치료를 병행한 후 HBV-DNA가 음전된 만성 B형 간염 환자 증례 보고

  • Han, Chang-woo (Dept. of Internal Medicine, Korean Medicine Hospital of Pusan National University and School of Korean Medicine, Pusan National University)
  • 한창우 (부산대학교 한방병원 한방내과, 부산대학교 한의학전문대학원)
  • Received : 2017.03.27
  • Accepted : 2017.05.26
  • Published : 2017.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

The patient presented to the clinic with the complaint of severe fatigue. The patient had been diagnosed with chronic hepatitis B a number of years earlier. Although he had used entecavir, an antiviral agent, for over two years, his HBV-DNA level had not dropped below undetectable levels. The fatigue seemed to be associated with chronic hepatitis B. Traditional Korean medicine (TKM) therapy for chronic hepatitis B was administered in conjunction with entecavir and at the same dose. The excessive fatigue gradually decreased following the treatment. On the 28th day, laboratory tests revealed that the patient's bilirubin level was slightly lower and that his HBV-DNA level had dropped below undetectable levels. The addition of TKM therapy may have contributed to the HBV-DNA clearance. No similar cases have been reported in Korea. Herein, we summarize the patient's progress.

Keywords

References

  1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30(12):2212-9. https://doi.org/10.1016/j.vaccine.2011.12.116
  2. Korea centers for disease control and prevention. Korea Health Statistics 2011: Korea National Health and Nutrition Examination Survey (KNHANES V-2). Cheongju: Korea centers for disease control and prevention; 2012, p. 464-5.
  3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095-128. https://doi.org/10.1016/S0140-6736(12)61728-0
  4. Weinbaum C, Williams I, Mast E, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57(RR-8):1-20.
  5. 中華中医藥學會. 中医內科常見病診療指南西医疾病部分. 北京: 中國中医藥出版社; 2008, p. 122-9.
  6. Woo HJ, Lee JH, Kim YC, Kim GS, Son CG, Jo JH, et al. Liver system internal medicine. 6th edition. Seoul: Nado publishing company; 2016, p. 9-11, 270-98.
  7. 蔡禹錫. 董氏奇穴集成. 首爾: 一中社; 1997, p. 251-5.
  8. Zhang L, Wang G, Hou W, Li P, Dulin A, Bonkovsky HL. Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology 2010;51(2):690-8. https://doi.org/10.1002/hep.23384
  9. Scaglioni PP, Melegari M, Wands JR. Recent advances in the molecular biology of hepatitis B virus. Baillieres Clin Gastroenterol 1996;10(2):207-25. https://doi.org/10.1016/S0950-3528(96)90003-2
  10. Chu CM, Liaw YF, Pao CC, Huang MJ. The etiology of acute hepatitis superimposed upon previously unrecognized asymptomatic HBsAg carriers. Hepatology 1989;9(3):452-6. https://doi.org/10.1002/hep.1840090319
  11. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991;13(4):627-31. https://doi.org/10.1002/hep.1840130403
  12. Alter HJ, Seeff LB, Kaplan PM, McAuliffe VJ, Wright EC, Gerin JL, et al. Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med 1976;295(17):909-13. https://doi.org/10.1056/NEJM197610212951701
  13. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130(3):678-86. https://doi.org/10.1053/j.gastro.2005.11.016
  14. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63(1):261-83. https://doi.org/10.1002/hep.28156
  15. Drugs.com. Available from: URL:https://www.drugs.com/monograph/ entecavir.html
  16. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354(10):1011-20. https://doi.org/10.1056/NEJMoa051287
  17. Jeong JS, Jeong UM, Lee JS, Yoon SW, Park JW. A case of repetitive drug-induced liver injury treated with Injinchunggan-tang. J Int Korean Med 2009;Oct:246-52.
  18. Kim HY, Bae JH, Choi ES, Jang EG, Lee JH, Kim YC. Effects of herbal medicine Injinchunggan -tang on steroid-induced symptoms in a patient with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome: a case report. J Int Korean Med 2016;37(3):560-7.